{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:47:52Z","timestamp":1777538872000,"version":"3.51.4"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Advances in translational neuroimmunology over the last two decades have revolutionized the treatment of relapsing forms of multiple sclerosis. A pathological hallmark of multiple sclerosis is the presence of leukocytes in the areas of disease activity in the CNS. Natalizumab inhibits the trafficking of lymphocytes from the blood into the brain and spinal cord by blocking the adhesion molecule \u03b14-integrin. Representing the enormous success of a molecular targeted approach, natalizumab was the first mAb approved for the treatment of relapsing\u2013remitting multiple sclerosis. However, only a few months after its approval, natalizumab was withdrawn from the market because of an unanticipated life threatening adverse effect: progressive multifocal leukoencephalopathy. Natalizumab was later reintroduced with required adherence to a strict monitoring program. In this article, we review the bench-to-bedside journey of natalizumab, along with the lessons learned from postmarketing studies.<\/jats:p>","DOI":"10.4049\/jimmunol.1601358","type":"journal-article","created":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T21:50:09Z","timestamp":1486417809000},"page":"1381-1386","source":"Crossref","is-referenced-by-count":23,"title":["Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology"],"prefix":"10.1093","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8866-6426","authenticated-orcid":false,"given":"Afsaneh","family":"Shirani","sequence":"first","affiliation":[{"name":"Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center , Dallas, TX 75390; and , Dallas, TX 75216"},{"name":"Neurology Section, VA North Texas Health Care System, Medical Service, Dallas VA Medical Center , Dallas, TX 75390; and , Dallas, TX 75216"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"St\u00fcve","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center , Dallas, TX 75390; and , Dallas, TX 75216"},{"name":"Neurology Section, VA North Texas Health Care System, Medical Service, Dallas VA Medical Center , Dallas, TX 75390; and , Dallas, TX 75216"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"2025030615030439600_r1","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/archneurol.2010.158","article-title":"Translational research in neurology and neuroscience 2010: multiple sclerosis","volume":"67","author":"St\u00fcve","year":"2010","journal-title":"Arch. Neurol."},{"key":"2025030615030439600_r2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"key":"2025030615030439600_r3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrneurol.2015.14","article-title":"Multiple sclerosis-a quiet revolution","volume":"11","author":"Ransohoff","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"2025030615030439600_r4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMra052130","article-title":"Multiple sclerosis--the plaque and its pathogenesis","volume":"354","author":"Frohman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2025030615030439600_r5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/ni1275","article-title":"Immune cell migration in inflammation: present and future therapeutic targets","volume":"6","author":"Luster","year":"2005","journal-title":"Nat. Immunol."},{"key":"2025030615030439600_r6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1527-3458.2007.00003.x","article-title":"Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases","volume":"13","author":"St\u00fcve","year":"2007","journal-title":"CNS Drug Rev."},{"key":"2025030615030439600_r7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1083\/jcb.201207175","article-title":"The discovery of natalizumab, a potent therapeutic for multiple sclerosis","volume":"199","author":"Steinman","year":"2012","journal-title":"J. Cell Biol."},{"key":"2025030615030439600_r8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40265-013-0030-6","article-title":"Drugs in development for relapsing multiple sclerosis","volume":"73","author":"Ali","year":"2013","journal-title":"Drugs"},{"key":"2025030615030439600_r9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"2025030615030439600_r10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1098\/rspb.1964.0001","article-title":"The route of re-circulation of lymphocytes in the rat","volume":"159","author":"Gowans","year":"1964","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"2025030615030439600_r11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1126\/science.272.5258.60","article-title":"Lymphocyte homing and homeostasis","volume":"272","author":"Butcher","year":"1996","journal-title":"Science"},{"key":"2025030615030439600_r12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0092-8674(94)90337-9","article-title":"Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm","volume":"76","author":"Springer","year":"1994","journal-title":"Cell"},{"key":"2025030615030439600_r13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/0092-8674(89)90775-7","article-title":"Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes","volume":"59","author":"Osborn","year":"1989","journal-title":"Cell"},{"key":"2025030615030439600_r14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0092-8674(90)90661-W","article-title":"VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4\/fibronectin binding site","volume":"60","author":"Elices","year":"1990","journal-title":"Cell"},{"key":"2025030615030439600_r15","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.4049\/jimmunol.154.11.5876","article-title":"T lymphocyte adhesion to human brain pericytes is mediated via very late antigen-4\/vascular cell adhesion molecule-1 interactions","volume":"154","author":"Verbeek","year":"1995","journal-title":"J. Immunol."},{"key":"2025030615030439600_r16","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1212\/WNL.52.5.1072","article-title":"A safety and pharmacokinetic study of intravenous natalizumab in patients with MS","volume":"52","author":"Sheremata","year":"1999","journal-title":"Neurology"},{"key":"2025030615030439600_r17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1191\/1352458504ms1084oa","article-title":"An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis","volume":"10","author":"Vollmer","year":"2004","journal-title":"Mult. Scler."},{"key":"2025030615030439600_r18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.53.3.466","article-title":"The effect of anti-alpha4 integrin antibody on brain lesion activity in MS","volume":"53","author":"Tubridy","year":"1999","journal-title":"Neurology"},{"key":"2025030615030439600_r19","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1212\/01.WNL.0000128136.79044.D6","article-title":"Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects","volume":"62","author":"O\u2019Connor","year":"2004","journal-title":"Neurology"},{"key":"2025030615030439600_r20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2025030615030439600_r21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","article-title":"GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology"},{"key":"2025030615030439600_r22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2025030615030439600_r23","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2025030615030439600_r24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285615615257","article-title":"Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis","volume":"9","author":"Sellebjerg","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"2025030615030439600_r25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3174\/ajnr.A2238","article-title":"Measuring myelin repair and axonal loss with diffusion tensor imaging","volume":"32","author":"Fox","year":"2011","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"2025030615030439600_r26","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3174\/ajnr.A4252","article-title":"Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis","volume":"36","author":"Wiebenga","year":"2015","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"2025030615030439600_r27","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1212\/WNL.0000000000000361","article-title":"Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial","volume":"82","author":"Romme Christensen","year":"2014","journal-title":"Neurology"},{"key":"2025030615030439600_r28","article-title":"Biogen Press Releases. Biogen reports top-line results from phase 3 study evaluating natalizumab in secondary progressive MS"},{"key":"2025030615030439600_r29","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0140-6736(16)00158-6","article-title":"Primary progressive multiple sclerosis--why we are failing","volume":"387","author":"Segal","year":"2016","journal-title":"Lancet"},{"key":"2025030615030439600_r30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1179\/016164106X98198","article-title":"Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab","volume":"28","author":"Berger","year":"2006","journal-title":"Neurol. Res."},{"key":"2025030615030439600_r31","first-page":"495","article-title":"The pathogenesis of progressive multifocal leukoencephalopathy","volume":"12","author":"Berger","year":"2011","journal-title":"Discov. Med."},{"key":"2025030615030439600_r32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2025030615030439600_r33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2025030615030439600_r34","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2025030615030439600_r35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences","volume":"353","author":"Berger","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2025030615030439600_r36","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. [Published erratum appears in 2010 Lancet Neurol. 9: 463.]","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol."},{"key":"2025030615030439600_r37","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann. Neurol."},{"key":"2025030615030439600_r38","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1212\/WNL.0000000000002586","article-title":"Punctate pattern: a promising imaging marker for the diagnosis of natalizumab-associated PML","volume":"86","author":"Hodel","year":"2016","journal-title":"Neurology"},{"key":"2025030615030439600_r39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"key":"2025030615030439600_r40","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"key":"2025030615030439600_r41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-011-0900-5","article-title":"Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy","volume":"123","author":"Metz","year":"2012","journal-title":"Acta Neuropathol."},{"key":"2025030615030439600_r42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneurol.2010.257","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy","volume":"68","author":"Miravalle","year":"2011","journal-title":"Arch. Neurol."},{"key":"2025030615030439600_r43","author":"Touch On-Line"},{"key":"2025030615030439600_r44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann. Neurol."},{"key":"2025030615030439600_r45","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2025030615030439600_r46","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","article-title":"Changes to anti-JCV antibody levels in a Swedish national MS cohort","volume":"84","author":"Warnke","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2025030615030439600_r47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s00415-015-7641-7","article-title":"Natalizumab in MS: JC antibody index","volume":"262","author":"Fung","year":"2015","journal-title":"J. Neurol."},{"key":"2025030615030439600_r48","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"2025030615030439600_r49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13365-016-0427-6","article-title":"Reassessing the risk of natalizumab-associated PML. [Published erratum appears in 2016 J. Neurovirol. 22: 536\u2013537.]","volume":"22","author":"Berger","year":"2016","journal-title":"J. Neurovirol."},{"key":"2025030615030439600_r50","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s13365-016-0431-x","article-title":"Erratum to: reassessing the risk of natalizumab-associated PML","volume":"22","author":"Berger","year":"2016","journal-title":"J. Neurovirol."},{"key":"2025030615030439600_r51","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"2025030615030439600_r52","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/1352458514531843","article-title":"Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?","volume":"20","author":"Cutter","year":"2014","journal-title":"Mult. Scler."},{"key":"2025030615030439600_r53","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","article-title":"Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients","volume":"70","author":"Vellinga","year":"2008","journal-title":"Neurology"},{"key":"2025030615030439600_r54","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516641775","article-title":"Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal","volume-title":"Mult. Scler","author":"Larochelle","year":"2016"},{"key":"2025030615030439600_r55","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1212\/01.wnl.0000327341.89587.76","article-title":"Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy","volume":"72","author":"St\u00fcve","year":"2009","journal-title":"Neurology"},{"key":"2025030615030439600_r56","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O\u2019Connor","year":"2011","journal-title":"Neurology"},{"key":"2025030615030439600_r57","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1586\/ern.11.109","article-title":"What happens when natalizumab therapy is stopped?","volume":"11","author":"Schaaf","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"2025030615030439600_r58","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516640609","article-title":"Th17 cells: a prognostic marker for MS rebound after natalizumab cessation?","volume-title":"Mult. Scler","author":"Haas","year":"2016"},{"key":"2025030615030439600_r59","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"key":"2025030615030439600_r60","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/NRL.0b013e318148c08e","article-title":"The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists","volume":"13","author":"Fox","year":"2007","journal-title":"Neurologist"},{"key":"2025030615030439600_r61","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1212\/WNL.0000000000002654","article-title":"Fingolimod-associated PML in a patient with prior immunosuppression","volume":"86","author":"Gyang","year":"2016","journal-title":"Neurology"},{"key":"2025030615030439600_r62","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJMc1415408","article-title":"PML in a patient with lymphocytopenia treated with dimethyl fumarate","volume":"372","author":"Rosenkranz","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/198\/4\/1381\/61448876\/1601358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/198\/4\/1381\/61448876\/1601358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T17:13:51Z","timestamp":1741281231000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/198\/4\/1381\/7954871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,2,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1601358","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2]]},"published":{"date-parts":[[2017,2]]}}}